
Lilly reports positive early data for JAK2 inhibitor in myelofibrosis
Eli Lilly and Company is presenting Phase 1 clinical findings for AJ1-11095, a first-in-class type II JAK2 inhibitor, at the 2026 European Hematology Association Annual Meeting in Stockholm. The drug targets patients with myelofibrosis who have previously failed to respond to standard type I JAK2 therapies.
























